Microbiome modulation as a novel therapeutic approach in chronic kidney disease.
Constipation
/ etiology
Diet, Protein-Restricted
Diet, Vegetarian
Disease Progression
Dysbiosis
/ complications
Gastrointestinal Microbiome
/ genetics
Humans
Intestinal Diseases
/ complications
Laxatives
/ therapeutic use
Nanotechnology
Prebiotics
/ administration & dosage
Probiotics
/ therapeutic use
Renal Insufficiency, Chronic
/ etiology
Synbiotics
/ administration & dosage
Uremia
/ etiology
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
6
11
2020
medline:
15
10
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
Gut dysbiosis has been implicated in the pathogenesis of chronic kidney disease (CKD). Interventions aimed at restoring gut microbiota have emerged as a potential therapeutic option in CKD. This review summarizes the current evidence on gut microbiota-targeted strategies in patients with CKD. A growing number of studies have shown that plant-based diets, low-protein diets, prebiotic, probiotic, and synbiotic supplementation, and constipation treatment may lead to favorable alterations in the gut microbiota. Current evidence suggests that the implementation of both plant-based and low-protein diets has potential benefits for the primary prevention of CKD, and for slowing CKD progression, with minimal risk of hyperkalemia and/or cachexia. The use of prebiotics, probiotics, and synbiotics and laxatives may have beneficial effects on uremic toxin generation, but their evidence is limited for the prevention and treatment of CKD. Recent advances in diagnostic technologies (e.g., high-throughput sequencing and nanotechnology) could enhance rapid diagnosis, monitoring, and design of effective therapeutic strategies for mitigating gut dysbiosis in CKD. Plant-based and low-protein diets, prebiotic, probiotic, and synbiotic supplementation, and constipation treatment represent novel gut microbiota-targeted strategies in the conservative management of CKD, which could improve clinical outcomes in CKD.
Identifiants
pubmed: 33148949
doi: 10.1097/MNH.0000000000000661
pii: 00041552-202101000-00010
doi:
Substances chimiques
Laxatives
0
Prebiotics
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-84Subventions
Organisme : NINDS NIH HHS
ID : R01 NS113337
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK091419
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK125586
Pays : United States
Références
Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83:308–315.
Pahl MV, Vaziri ND. The chronic kidney disease – colonic axis. Semin Dial 2015; 28:459–463.
Sumida K, Kovesdy CP. The gut–kidney–heart axis in chronic kidney disease. Physiol Int 2019; 106:195–206.
Ramezani A, Massy ZA, Meijers B, et al. Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis 2016; 67:483–498.
Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998; 95:6578–6583.
Malnick S, Melzer E. Human microbiome: from the bathroom to the bedside. World J Gastrointest Pathophysiol 2015; 6:79–85.
Siezen RJ, Kleerebezem M. The human gut microbiome: are we our enterotypes? Microb Biotechnol 2011; 4:550–553.
Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007; 449:804–810.
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635–1638.
Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489:242–249.
Levy M, Thaiss CA, Elinav E. Metabolites: messengers between the microbiota and the immune system. Genes Dev 2016; 30:1589–1597.
Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997; 6: (Suppl 1): S43–S45.
Hooper LV, Midtvedt T, Gordon JI. How host–microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22:283–307.
Hylemon PB, Harder J. Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. FEMS Microbiol Rev 1998; 22:475–488.
Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014; 39:230–237.
Gerritsen J, Smidt H, Rijkers GT, et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011; 6:209–240.
Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2016; 31:737–746.
Kang Y, Cai Y. Gut microbiota and obesity: implications for fecal microbiota transplantation therapy. Hormones (Athens) 2017; 16:223–234.
Adnan S, Nelson JW, Ajami NJ, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics 2017; 49:96–104.
Raskov H, Burcharth J, Pommergaard HC. Linking gut microbiota to colorectal cancer. J Cancer 2017; 8:3378–3395.
Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015; 26:26191.
Simenhoff ML, Dunn SR, Zollner GP, et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22:92–96.
Hida M, Aiba Y, Sawamura S, et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74:349–355.
Wang F, Jiang H, Shi K, et al. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton) 2012; 17:733–738.
Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012; 21:587–592.
Kalantar-Zadeh K, Kopple JD, Deepak S, et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002; 12:17–31.
Lau WL, Savoj J, Nakata MB, et al. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci (Lond) 2018; 132:509–522.
Kortman GAM, Reijnders D, Swinkels DW. Oral iron supplementation: potential implications for the gut microbiome and metabolome in patients with CKD. Hemodial Int 2017; 21: (Suppl 1): S28–S36.
Lau WL, Vaziri ND, Nunes ACF, et al. The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease. J Pharmacol Exp Ther 2018; 367:452–460.
Vangay P, Ward T, Gerber JS, et al. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 2015; 17:553–564.
Goraya N, Wesson DE. Acid-base status and progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21:552–556.
Wu MJ, Chang CS, Cheng CH, et al. Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004; 44:322–327.
Andersen K, Kesper MS, Marschner JA, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol 2017; 28:76–83.
Meijers B, Farre R, Dejongh S, et al. Intestinal barrier function in chronic kidney disease. Toxins (Basel) 2018; 10:298.
Terpstra ML, Singh R, Geerlings SE, et al. Measurement of the intestinal permeability in chronic kidney disease. World J Nephrol 2016; 5:378–388.
Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999; 34:1975–1981.
Evenepoel P, Meijers BK, Bammens BR, et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009; 76: (Suppl 114): S12–S19.
Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575–1584.
Kalantar-Zadeh K, Joshi S, Schlueter R, et al. Plant-dominant low-protein diet for conservative management of chronic kidney disease. Nutrients 2020; 12:1931.
Snelson M, Kellow NJ, Coughlan MT. Modulation of the gut microbiota by resistant starch as a treatment of chronic kidney diseases: evidence of efficacy and mechanistic insights. Adv Nutr 2019; 10:303–320.
Adair KE, Bowden RG. Ameliorating chronic kidney disease using a whole food plant-based diet. Nutrients 2020; 12:1007.
Koppe L, Fouque D. Microbiota and prebiotics modulation of uremic toxin generation. Panminerva Med 2017; 59:173–187.
Natarajan R, Pechenyak B, Vyas U, et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int 2014; 2014:568571.
Guida B, Germano R, Trio R, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis 2014; 24:1043–1049.
Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Rep 2020; 5:121–134.
Joshi S, Hashmi S, Shah S, et al. Plant-based diets for prevention and management of chronic kidney disease. Curr Opin Nephrol Hypertens 2020; 29:16–21.
Hamaker BR, Tuncil YE. A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. J Mol Biol 2014; 426:3838–3850.
Zimmer J, Lange B, Frick JS, et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66:53–60.
Kim MS, Hwang SS, Park EJ, et al. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013; 5:765–775.
Chassard C, Lacroix C. Carbohydrates and the human gut microbiota. Curr Opin Clin Nutr Metab Care 2013; 16:453–460.
Lattimer JM, Haub MD. Effects of dietary fiber and its components on metabolic health. Nutrients 2010; 2:1266–1289.
Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336:1262–1267.
Kalantar-Zadeh K, Berean KJ, Burgell RE, et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 2019; 16:733–747.
Kasubuchi M, Hasegawa S, Hiramatsu T, et al. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 2015; 7:2839–2849.
Wang HB, Wang PY, Wang X, et al. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 2012; 57:3126–3135.
Huang W, Guo HL, Deng X, et al. Short-chain fatty acids inhibit oxidative stress and inflammation in mesangial cells induced by high glucose and lipopolysaccharide. Exp Clin Endocrinol Diabetes 2017; 125:98–105.
Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. Adv Immunol 2014; 121:91–119.
van der Beek CM, Dejong CHC, Troost FJ, et al. Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing. Nutr Rev 2017; 75:286–305.
Kieffer DA, Piccolo BD, Vaziri ND, et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 2016; 310:F857–F871.
Vaziri ND, Liu SM, Lau WL, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014; 9:e114881.
Lam YY, Ha CW, Hoffmann JM, et al. Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice. Obesity (Silver Spring) 2015; 23:1429–1439.
Fava F, Gitau R, Griffin BA, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population. Int J Obes (Lond) 2013; 37:216–223.
Kennedy A, Martinez K, Chuang CC, et al. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr 2009; 139:1–4.
O'Shea EF, Cotter PD, Stanton C, et al. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol 2012; 152:189–205.
Chen X, Wei G, Jalili T, et al. The associations of plant protein intake with all-cause mortality in CKD. Am J Kidney Dis 2016; 67:423–430.
Haring B, Selvin E, Liang M, et al. Dietary protein sources and risk for incident chronic kidney disease: results from the Atherosclerosis Risk in Communities (ARIC) study. J Ren Nutr 2017; 27:233–242.
Kim H, Caulfield LE, Garcia-Larsen V, et al. Plant-based diets and incident CKD and kidney function. Clin J Am Soc Nephrol 2019; 14:682–691.
Lin J, Hu FB, Curhan GC. Associations of diet with albuminuria and kidney function decline. Clin J Am Soc Nephrol 2010; 5:836–843.
Kontessis P, Jones S, Dodds R, et al. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int 1990; 38:136–144.
Kamper AL, Strandgaard S. Long-term effects of high-protein diets on renal function. Annu Rev Nutr 2017; 37:347–369.
Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012; 7:982–988.
Goraya N, Simoni J, Jo CH, et al. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 2014; 86:1031–1038.
Goraya N, Simoni J, Jo CH, et al. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol 2013; 8:371–381.
Goraya N, Simoni J, Jo C, et al. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 2012; 81:86–93.
Gluba-Brzozka A, Franczyk B, Rysz J. Vegetarian diet in chronic kidney disease – a friend or foe. Nutrients 2017; 9:374.
Clarys P, Deliens T, Huybrechts I, et al. Comparison of nutritional quality of the vegan, vegetarian, semi-vegetarian, pesco-vegetarian and omnivorous diet. Nutrients 2014; 6:1318–1332.
Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:257–264.
Krishnamurthy VM, Wei G, Baird BC, et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012; 81:300–306.
Xu H, Huang X, Riserus U, et al. Dietary fiber, kidney function, inflammation, and mortality risk. Clin J Am Soc Nephrol 2014; 9:2104–2110.
Cupisti A, D’Alessandro C, Gesualdo L, et al. Non-traditional aspects of renal diets: focus on fiber, alkali and vitamin K1 intake. Nutrients 2017; 9:444.
Evenepoel P, Meijers BK. Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. Kidney Int 2012; 81:227–229.
Rhee CM, Ahmadi SF, Kovesdy CP, et al. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J Cachexia Sarcopenia Muscle 2018; 9:235–245.
Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med 2017; 377:1765–1776.
Cummings JH. Fermentation in the human large intestine: evidence and implications for health. Lancet 1983; 1:1206–1209.
Martinez AW, Recht NS, Hostetter TH, et al. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16:3430–3436.
Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l -carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19:576–585.
Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57–63.
Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551–1558.
Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5:1182–1189.
Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine- N -oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 2016; 27:305–313.
Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine- N -oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116:448–455.
Black AP, Anjos JS, Cardozo L, et al. Does low-protein diet influence the uremic toxin serum levels from the gut microbiota in nondialysis chronic kidney disease patients? J Ren Nutr 2018; 28:208–214.
Lai S, Molfino A, Testorio M, et al. Effect of low-protein diet and inulin on microbiota and clinical parameters in patients with chronic kidney disease. Nutrients 2019; 11:3006.
Dhar D, Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res 2020; 285:198018.
Glennas A, Brath HK, Bergaust B. Ocular side effects of chloroquine treatment of rheumatoid arthritis patients. Tidsskr Nor Laegeforen 1980; 100:902–903.
McFarlane C, Ramos CI, Johnson DW, et al. Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr 2019; 29:209–220.
Rossi M, Johnson DW, Morrison M, et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol 2016; 11:223–231.
Meijers BK, De Preter V, Verbeke K, et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010; 25:219–224.
Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and incident CKD. J Am Soc Nephrol 2017; 28:1248–1258.
Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and risk of death and cardiovascular events. Atherosclerosis 2019; 281:114–120.
Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus 2016; 5:1130.
Khalif IL, Quigley EM, Konovitch EA, et al. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005; 37:838–849.
Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62:159–176.
Parthasarathy G, Chen J, Chen X, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology 2016; 150:367–379.e1.
Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100:2560–2568.
Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil 2014; 20:31–40.
Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144:218–238.
De Schryver AM, Samsom M, Smout AI. Effects of a meal and bisacodyl on colonic motility in healthy volunteers and patients with slow-transit constipation. Dig Dis Sci 2003; 48:1206–1212.
Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232–242.
Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011; 33:895–901.
Sumida K, Dashputre AA, Potukuchi PK, et al. Laxative use in patients with advanced chronic kidney disease transitioning to dialysis. Nephrol Dial Transplant 2020; doi: 10.1093/ndt/gfaa205. Online ahead of print.
doi: 10.1093/ndt/gfaa205.
Tayebi-Khosroshahi H, Habibzadeh A, Niknafs B, et al. The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease: a randomized clinical trial. J Renal Inj Prev 2016; 5:162–167.
Sueyoshi M, Fukunaga M, Mei M, et al. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol 2019; 23:908–919.
Mishima E, Fukuda S, Shima H, et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 2015; 26:1787–1794.
Nanto-Hara F, Kanemitsu Y, Fukuda S, et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant 2019; 35:250–264.
Brugere JF, Mihajlovski A, Missaoui M, et al. Tools for stools: the challenge of assessing human intestinal microbiota using molecular diagnostics. Expert Rev Mol Diagn 2009; 9:353–365.
Grice EA. The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease. Semin Cutan Med Surg 2014; 33:98–103.
Lane DJ, Pace B, Olsen GJ, et al. Rapid determination of 16S ribosomal RNA sequences for phylogenetic analyses. Proc Natl Acad Sci U S A 1985; 82:6955–6959.
Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 2013; 498:367–370.
Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther 2003; 3:655–663.
Weiss PS. Opportunities for nanoscience and nanotechnology in studying microbiomes. ACS Nano 2016; 10:1–2.
Biteen JS, Blainey PC, Cardon ZG, et al. Tools for the microbiome: nano and beyond. ACS Nano 2016; 10:6–37.
Nakhleh MK, Amal H, Jeries R, et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. ACS Nano 2017; 11:112–125.
Kalantar-Zadeh K, Ha N, Ou JZ, et al. Ingestible sensors. ACS Sens 2017; 2:468–483.
Singh T, Shukla S, Kumar P, et al. Application of nanotechnology in food science: perception and overview. Front Microbiol 2017; 8:1501.
Hua S, Marks E, Schneider JJ, et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 2015; 11:1117–1132.
Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, et al. Considering the effects of microbiome and diet on SARS-CoV-2 infection: nanotechnology roles. ACS Nano 2020; 14:5179–5182.
Guo L, McLean JS, Yang Y, et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc Natl Acad Sci U S A 2015; 112:7569–7574.
Eckert R, He J, Yarbrough DK, et al. Targeted killing of Streptococcus mutans by a pheromone-guided ‘smart’ antimicrobial peptide. Antimicrob Agents Chemother 2006; 50:3651–3657.
Prakash S, Chang TM. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med 1996; 2:883–887.